Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2013-09

AUTHORS

Omar Abdel-Rahman, Manal Abdel-Wahab, Mohammed Shaker, Sherif Abdel-Wahab, Mohammed Elbassiony, Mahmoud Ellithy

ABSTRACT

The only approved systemic therapy for patients with advanced hepatocellular carcinoma (HCC) till now is sorafenib. A preliminary study suggested that capecitabine, an oral fluoropyrimidine, may be effective in advanced HCC. We have tested this hypothesis in this phase 2 study. In this single-center, phase 2, open-label trial, we randomly assigned 52 patients with advanced HCC who had not received previous systemic treatment to receive either sorafenib (at a dose of 400 mg twice daily) or capecitabine (1,000 mg/m(2) twice daily) (day 1-day 14). Primary outcome was progression-free survival. Secondary outcomes included the overall survival and safety. Median overall survival was 7.05 months in the sorafenib group and 5.07 months in the capecitabine group (hazard ratio in the capecitabine group 2.36; 95 % confidence interval 1.174-4.74; P < 0.016). The median progression-free survival was 6 months in the sorafenib group and 4 months in the capecitabine group (P < 0.005). Three patients in the sorafenib group (11.5 %) and one patient in the capecitabine group (3 %) had a partial response; one patient (3 %) had a complete response in the sorafenib group. Hand-foot skin reaction was more frequent in the sorafenib group, hyperbilirubinemia was more common in the capecitabine group, and diarrhea was equivalent between both groups. In patients with advanced HCC, capecitabine is inferior to sorafenib in terms of median progression-free survival and overall survival, and it should not be used alone for the treatment of advanced HCC, but rather, combination therapy with sorafenib should be considered. More... »

PAGES

655

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12032-013-0655-z

DOI

http://dx.doi.org/10.1007/s12032-013-0655-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1024384635

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/23824645


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antimetabolites, Antineoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Capecitabine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Hepatocellular", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deoxycytidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorouracil", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Niacinamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phenylurea Compounds", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Ain Shams University", 
          "id": "https://www.grid.ac/institutes/grid.7269.a", 
          "name": [
            "Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Lofty Elsayed Street, Abbaseya, Cairo, Egypt"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Abdel-Rahman", 
        "givenName": "Omar", 
        "id": "sg:person.0671451062.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0671451062.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ain Shams University", 
          "id": "https://www.grid.ac/institutes/grid.7269.a", 
          "name": [
            "Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Lofty Elsayed Street, Abbaseya, Cairo, Egypt"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Abdel-Wahab", 
        "givenName": "Manal", 
        "id": "sg:person.01122526057.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122526057.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ain Shams University", 
          "id": "https://www.grid.ac/institutes/grid.7269.a", 
          "name": [
            "Tropical Medicine Department, Faculty of Medicine, Ain Shams University, Abbaseya, Cairo, Egypt"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shaker", 
        "givenName": "Mohammed", 
        "id": "sg:person.01170641257.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01170641257.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ain Shams University", 
          "id": "https://www.grid.ac/institutes/grid.7269.a", 
          "name": [
            "Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Lofty Elsayed Street, Abbaseya, Cairo, Egypt"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Abdel-Wahab", 
        "givenName": "Sherif", 
        "id": "sg:person.01113730576.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01113730576.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ain Shams University", 
          "id": "https://www.grid.ac/institutes/grid.7269.a", 
          "name": [
            "Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Lofty Elsayed Street, Abbaseya, Cairo, Egypt"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Elbassiony", 
        "givenName": "Mohammed", 
        "id": "sg:person.01305067657.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01305067657.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ain Shams University", 
          "id": "https://www.grid.ac/institutes/grid.7269.a", 
          "name": [
            "Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Lofty Elsayed Street, Abbaseya, Cairo, Egypt"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ellithy", 
        "givenName": "Mahmoud", 
        "id": "sg:person.01353203057.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01353203057.41"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1093/annonc/mds487", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000855554"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.03.7234", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004554821"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000342425", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010365731"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.01.3441", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012786175"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.19.7996", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015612152"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0042875", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015676476"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1349-7006.2007.00648.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017959937"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(08)70285-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018829845"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.transproceed.2012.07.151", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019054991"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0168-8278(01)00130-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021007716"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/hep.24710", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026154821"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jhep.2012.06.014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031567062"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1586/era.12.58", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033515722"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000343091", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038427252"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.20368", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043000578"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0168-8278(12)61013-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046034746"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa0708857", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053513212"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4149/av_2012_03_235", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072260976"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2013-09", 
    "datePublishedReg": "2013-09-01", 
    "description": "The only approved systemic therapy for patients with advanced hepatocellular carcinoma (HCC) till now is sorafenib. A preliminary study suggested that capecitabine, an oral fluoropyrimidine, may be effective in advanced HCC. We have tested this hypothesis in this phase 2 study. In this single-center, phase 2, open-label trial, we randomly assigned 52 patients with advanced HCC who had not received previous systemic treatment to receive either sorafenib (at a dose of 400\u00a0mg twice daily) or capecitabine (1,000\u00a0mg/m(2) twice daily) (day 1-day 14). Primary outcome was progression-free survival. Secondary outcomes included the overall survival and safety. Median overall survival was 7.05\u00a0months in the sorafenib group and 5.07\u00a0months in the capecitabine group (hazard ratio in the capecitabine group 2.36; 95\u00a0% confidence interval 1.174-4.74; P\u00a0<\u00a00.016). The median progression-free survival was 6\u00a0months in the sorafenib group and 4\u00a0months in the capecitabine group (P\u00a0<\u00a00.005). Three patients in the sorafenib group (11.5\u00a0%) and one patient in the capecitabine group (3\u00a0%) had a partial response; one patient (3\u00a0%) had a complete response in the sorafenib group. Hand-foot skin reaction was more frequent in the sorafenib group, hyperbilirubinemia was more common in the capecitabine group, and diarrhea was equivalent between both groups. In patients with advanced HCC, capecitabine is inferior to sorafenib in terms of median progression-free survival and overall survival, and it should not be used alone for the treatment of advanced HCC, but rather, combination therapy with sorafenib should be considered. ", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s12032-013-0655-z", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094524", 
        "issn": [
          "1357-0560", 
          "1559-131X"
        ], 
        "name": "Medical Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "30"
      }
    ], 
    "name": "Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma", 
    "pagination": "655", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "742bc2d04175273d69360d92236b714370527a4b6dbd554c6dbe743851720670"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "23824645"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9435512"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12032-013-0655-z"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1024384635"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12032-013-0655-z", 
      "https://app.dimensions.ai/details/publication/pub.1024384635"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T13:20", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8659_00000522.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs12032-013-0655-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12032-013-0655-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12032-013-0655-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12032-013-0655-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12032-013-0655-z'


 

This table displays all metadata directly associated to this object as RDF triples.

215 TRIPLES      21 PREDICATES      61 URIs      35 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12032-013-0655-z schema:about N0e504b20bc7742019cd90a7861a42b7a
2 N266953e9580147928cec7fb6531dccc7
3 N3aa1afe5df7d4c1a9cae44c0bdec6a9c
4 N3c989e1b53bd47e0945db3c197c43ccb
5 N4615260b42ed49f5845946da21cf281f
6 N680dea0dd3aa433ca23dff51aef3ecb6
7 N6bd8fe7c1e044ae79473efc6e1862da4
8 N7e8334ebfccd42eb98817517bfb91e9d
9 Na80fe7f30039455dbd40502ef7eed168
10 Nbdda5543fc0f4994a67e50327669be62
11 Nc0a5c2dbf7a149a29fc6ea06ff22f876
12 Nc5777c480b59489ea7c1e84013f1e8ef
13 Nef473b27598b47b3806d23bbbacdd19f
14 Nf95fba77a6844f43a3a30c52e070c45f
15 anzsrc-for:11
16 anzsrc-for:1103
17 schema:author N0b363e59209c4b49aea515665aeb913d
18 schema:citation https://doi.org/10.1002/cncr.20368
19 https://doi.org/10.1002/hep.24710
20 https://doi.org/10.1016/j.jhep.2012.06.014
21 https://doi.org/10.1016/j.transproceed.2012.07.151
22 https://doi.org/10.1016/s0168-8278(01)00130-1
23 https://doi.org/10.1016/s0168-8278(12)61013-7
24 https://doi.org/10.1016/s1470-2045(08)70285-7
25 https://doi.org/10.1056/nejmoa0708857
26 https://doi.org/10.1093/annonc/mds487
27 https://doi.org/10.1111/j.1349-7006.2007.00648.x
28 https://doi.org/10.1159/000342425
29 https://doi.org/10.1159/000343091
30 https://doi.org/10.1200/jco.2005.01.3441
31 https://doi.org/10.1200/jco.2005.03.7234
32 https://doi.org/10.1200/jco.2008.19.7996
33 https://doi.org/10.1371/journal.pone.0042875
34 https://doi.org/10.1586/era.12.58
35 https://doi.org/10.4149/av_2012_03_235
36 schema:datePublished 2013-09
37 schema:datePublishedReg 2013-09-01
38 schema:description The only approved systemic therapy for patients with advanced hepatocellular carcinoma (HCC) till now is sorafenib. A preliminary study suggested that capecitabine, an oral fluoropyrimidine, may be effective in advanced HCC. We have tested this hypothesis in this phase 2 study. In this single-center, phase 2, open-label trial, we randomly assigned 52 patients with advanced HCC who had not received previous systemic treatment to receive either sorafenib (at a dose of 400 mg twice daily) or capecitabine (1,000 mg/m(2) twice daily) (day 1-day 14). Primary outcome was progression-free survival. Secondary outcomes included the overall survival and safety. Median overall survival was 7.05 months in the sorafenib group and 5.07 months in the capecitabine group (hazard ratio in the capecitabine group 2.36; 95 % confidence interval 1.174-4.74; P < 0.016). The median progression-free survival was 6 months in the sorafenib group and 4 months in the capecitabine group (P < 0.005). Three patients in the sorafenib group (11.5 %) and one patient in the capecitabine group (3 %) had a partial response; one patient (3 %) had a complete response in the sorafenib group. Hand-foot skin reaction was more frequent in the sorafenib group, hyperbilirubinemia was more common in the capecitabine group, and diarrhea was equivalent between both groups. In patients with advanced HCC, capecitabine is inferior to sorafenib in terms of median progression-free survival and overall survival, and it should not be used alone for the treatment of advanced HCC, but rather, combination therapy with sorafenib should be considered.
39 schema:genre research_article
40 schema:inLanguage en
41 schema:isAccessibleForFree false
42 schema:isPartOf N8abc894614de4b34913049b33e797d18
43 Na3ee1e77d7d2467c8179ae4eb67271b5
44 sg:journal.1094524
45 schema:name Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma
46 schema:pagination 655
47 schema:productId N34078c857ced45bf9792ec7e55ee783c
48 N59dac5fec8104de2800c88725f7d0fee
49 N8832682718a041459d5d917709004170
50 Ndff4614252574a1f9cfa8f71df732d09
51 Nf6e26ceef3664d8788ccf9225d9df02e
52 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024384635
53 https://doi.org/10.1007/s12032-013-0655-z
54 schema:sdDatePublished 2019-04-10T13:20
55 schema:sdLicense https://scigraph.springernature.com/explorer/license/
56 schema:sdPublisher N646446f844894495871edcc675a82212
57 schema:url http://link.springer.com/10.1007%2Fs12032-013-0655-z
58 sgo:license sg:explorer/license/
59 sgo:sdDataset articles
60 rdf:type schema:ScholarlyArticle
61 N0b363e59209c4b49aea515665aeb913d rdf:first sg:person.0671451062.54
62 rdf:rest Nbed1ba35130c431f95e354d7c7ceb51b
63 N0e504b20bc7742019cd90a7861a42b7a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
64 schema:name Phenylurea Compounds
65 rdf:type schema:DefinedTerm
66 N266953e9580147928cec7fb6531dccc7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
67 schema:name Disease-Free Survival
68 rdf:type schema:DefinedTerm
69 N34078c857ced45bf9792ec7e55ee783c schema:name dimensions_id
70 schema:value pub.1024384635
71 rdf:type schema:PropertyValue
72 N3aa1afe5df7d4c1a9cae44c0bdec6a9c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Fluorouracil
74 rdf:type schema:DefinedTerm
75 N3c989e1b53bd47e0945db3c197c43ccb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Capecitabine
77 rdf:type schema:DefinedTerm
78 N4615260b42ed49f5845946da21cf281f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Humans
80 rdf:type schema:DefinedTerm
81 N554ddc6755c5470ebd8b85beffe7b165 rdf:first sg:person.01305067657.09
82 rdf:rest Nc1acb41204a34eeeb6bf9c288f83d6e3
83 N59dac5fec8104de2800c88725f7d0fee schema:name pubmed_id
84 schema:value 23824645
85 rdf:type schema:PropertyValue
86 N646446f844894495871edcc675a82212 schema:name Springer Nature - SN SciGraph project
87 rdf:type schema:Organization
88 N680dea0dd3aa433ca23dff51aef3ecb6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Adult
90 rdf:type schema:DefinedTerm
91 N6bd8fe7c1e044ae79473efc6e1862da4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Deoxycytidine
93 rdf:type schema:DefinedTerm
94 N7e8334ebfccd42eb98817517bfb91e9d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Liver Neoplasms
96 rdf:type schema:DefinedTerm
97 N80c0642ebe20480788a7cfe0569210fc rdf:first sg:person.01113730576.52
98 rdf:rest N554ddc6755c5470ebd8b85beffe7b165
99 N8832682718a041459d5d917709004170 schema:name readcube_id
100 schema:value 742bc2d04175273d69360d92236b714370527a4b6dbd554c6dbe743851720670
101 rdf:type schema:PropertyValue
102 N8abc894614de4b34913049b33e797d18 schema:issueNumber 3
103 rdf:type schema:PublicationIssue
104 Na3ee1e77d7d2467c8179ae4eb67271b5 schema:volumeNumber 30
105 rdf:type schema:PublicationVolume
106 Na80fe7f30039455dbd40502ef7eed168 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Antimetabolites, Antineoplastic
108 rdf:type schema:DefinedTerm
109 Nbdda5543fc0f4994a67e50327669be62 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Carcinoma, Hepatocellular
111 rdf:type schema:DefinedTerm
112 Nbed1ba35130c431f95e354d7c7ceb51b rdf:first sg:person.01122526057.58
113 rdf:rest Nd2acbafbab0c4a3c97d9a912f89806a3
114 Nc0a5c2dbf7a149a29fc6ea06ff22f876 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Niacinamide
116 rdf:type schema:DefinedTerm
117 Nc1acb41204a34eeeb6bf9c288f83d6e3 rdf:first sg:person.01353203057.41
118 rdf:rest rdf:nil
119 Nc5777c480b59489ea7c1e84013f1e8ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Middle Aged
121 rdf:type schema:DefinedTerm
122 Nd2acbafbab0c4a3c97d9a912f89806a3 rdf:first sg:person.01170641257.79
123 rdf:rest N80c0642ebe20480788a7cfe0569210fc
124 Ndff4614252574a1f9cfa8f71df732d09 schema:name nlm_unique_id
125 schema:value 9435512
126 rdf:type schema:PropertyValue
127 Nef473b27598b47b3806d23bbbacdd19f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Antineoplastic Agents
129 rdf:type schema:DefinedTerm
130 Nf6e26ceef3664d8788ccf9225d9df02e schema:name doi
131 schema:value 10.1007/s12032-013-0655-z
132 rdf:type schema:PropertyValue
133 Nf95fba77a6844f43a3a30c52e070c45f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Aged
135 rdf:type schema:DefinedTerm
136 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
137 schema:name Medical and Health Sciences
138 rdf:type schema:DefinedTerm
139 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
140 schema:name Clinical Sciences
141 rdf:type schema:DefinedTerm
142 sg:journal.1094524 schema:issn 1357-0560
143 1559-131X
144 schema:name Medical Oncology
145 rdf:type schema:Periodical
146 sg:person.01113730576.52 schema:affiliation https://www.grid.ac/institutes/grid.7269.a
147 schema:familyName Abdel-Wahab
148 schema:givenName Sherif
149 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01113730576.52
150 rdf:type schema:Person
151 sg:person.01122526057.58 schema:affiliation https://www.grid.ac/institutes/grid.7269.a
152 schema:familyName Abdel-Wahab
153 schema:givenName Manal
154 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122526057.58
155 rdf:type schema:Person
156 sg:person.01170641257.79 schema:affiliation https://www.grid.ac/institutes/grid.7269.a
157 schema:familyName Shaker
158 schema:givenName Mohammed
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01170641257.79
160 rdf:type schema:Person
161 sg:person.01305067657.09 schema:affiliation https://www.grid.ac/institutes/grid.7269.a
162 schema:familyName Elbassiony
163 schema:givenName Mohammed
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01305067657.09
165 rdf:type schema:Person
166 sg:person.01353203057.41 schema:affiliation https://www.grid.ac/institutes/grid.7269.a
167 schema:familyName Ellithy
168 schema:givenName Mahmoud
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01353203057.41
170 rdf:type schema:Person
171 sg:person.0671451062.54 schema:affiliation https://www.grid.ac/institutes/grid.7269.a
172 schema:familyName Abdel-Rahman
173 schema:givenName Omar
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0671451062.54
175 rdf:type schema:Person
176 https://doi.org/10.1002/cncr.20368 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043000578
177 rdf:type schema:CreativeWork
178 https://doi.org/10.1002/hep.24710 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026154821
179 rdf:type schema:CreativeWork
180 https://doi.org/10.1016/j.jhep.2012.06.014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031567062
181 rdf:type schema:CreativeWork
182 https://doi.org/10.1016/j.transproceed.2012.07.151 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019054991
183 rdf:type schema:CreativeWork
184 https://doi.org/10.1016/s0168-8278(01)00130-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021007716
185 rdf:type schema:CreativeWork
186 https://doi.org/10.1016/s0168-8278(12)61013-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046034746
187 rdf:type schema:CreativeWork
188 https://doi.org/10.1016/s1470-2045(08)70285-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018829845
189 rdf:type schema:CreativeWork
190 https://doi.org/10.1056/nejmoa0708857 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053513212
191 rdf:type schema:CreativeWork
192 https://doi.org/10.1093/annonc/mds487 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000855554
193 rdf:type schema:CreativeWork
194 https://doi.org/10.1111/j.1349-7006.2007.00648.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1017959937
195 rdf:type schema:CreativeWork
196 https://doi.org/10.1159/000342425 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010365731
197 rdf:type schema:CreativeWork
198 https://doi.org/10.1159/000343091 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038427252
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1200/jco.2005.01.3441 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012786175
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1200/jco.2005.03.7234 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004554821
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1200/jco.2008.19.7996 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015612152
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1371/journal.pone.0042875 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015676476
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1586/era.12.58 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033515722
209 rdf:type schema:CreativeWork
210 https://doi.org/10.4149/av_2012_03_235 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072260976
211 rdf:type schema:CreativeWork
212 https://www.grid.ac/institutes/grid.7269.a schema:alternateName Ain Shams University
213 schema:name Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Lofty Elsayed Street, Abbaseya, Cairo, Egypt
214 Tropical Medicine Department, Faculty of Medicine, Ain Shams University, Abbaseya, Cairo, Egypt
215 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...